Details checkedClinical trial listing onlyHistorical/discontinuedCheckedregistry

OHSU Acamprosate Tinnitus Study

Also known as: Acamprosate, Campral, Clinical Trial of Acamprosate for Tinnitus, NCT00596531

Institution-led study

Primary source

Sponsor / Institution

Institution-led study

Program Type

Therapeutic

Modality

Small Molecule

Stage

Phase 1

Status

Completed

Target Gene

—

Route / Mode

Oral

Confidence

84%

Status Confidence

Status needs checking

Evidence Strength

Needs more support

Last Reviewed

2026-06-10

Geography

United States

Population

adult, tinnitus

Trial IDs

Mechanism

Historical Phase 1 academic trial evaluating oral acamprosate/Campral versus placebo in tinnitus.

Indications

Tinnitus

Notes

Verified as a real completed OHSU Phase 1 acamprosate tinnitus trial. No active commercial tinnitus development program was established in this pass, so HearScape should treat it as a historical academic repurposing study.

Evidence & Sources

1 structured sources

clinicaltrials

Supports: canonicalName, aliases, company, allCompanies, isIndustrySponsored, programType, modality, mechanism...

IDs: NCT00596531

Open

Key Events

2008-01-01

Registry lists study start for OHSU acamprosate tinnitus trial

2013-11-01

Registry lists actual completion of acamprosate tinnitus trial

Clinical Trials (1)

NCT00596531

Data Checks

institution-led-studyregistry-only-evidencehistorical-studygeneric-repurposing-study

Related Programs

PEDMARK by Fennec Pharmaceuticals

Company: Fennec Pharmaceuticals · Small Molecule · Marketed

SENS-401 (Arazasetron) by Sensorion

Company: Sensorion · Small Molecule · Phase 2

AC102 by AudioCure Pharma

Company: AudioCure Pharma · Small Molecule · Phase 2

SPI-1005 by Sound Pharmaceuticals

Company: Sound Pharmaceuticals · Small Molecule · Phase 3

ACOU085 by Acousia Therapeutics

Company: Acousia Therapeutics GmbH · Small Molecule · Phase 2

CIL001 (Paliroden) by Cilcare

Company: Cilcare SAS · Small Molecule · Phase 1/2